Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 nov. 2023 10h37 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
27 juil. 2023 11h33 HE
|
The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
11 juil. 2023 09h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
27 juin 2023 07h15 HE
|
Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
22 mars 2023 13h22 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
ACQUISITION OF MCBURNEY APPROVED
23 févr. 2023 06h24 HE
|
DFDS A/S
COMPANY ANNOUNCEMENT no. 09 - 23 February 2023 On 29 December 2022, DFDS announced it had entered into an agreement to acquire 100% of McBurney Transport Group. Completion of the acquisition was...
KØB AF MCBURNEY GODKENDT
23 févr. 2023 06h24 HE
|
DFDS A/S
SELSKABSMEDDELELSE nr. 09 - 23. februar 2023 Den 29. december 2022 offentliggjorde DFDS, at der var indgået en aftale om at købe 100% af McBurney Transport Group. Gennemførsel af transaktionen var...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
21 févr. 2023 07h05 HE
|
uniQure Inc.
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
14 févr. 2023 20h40 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...